Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses of platinum compounds leading to increased tolerability. Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised medicine, are being investigated. Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“To date, four main mechanisms able to induce platinum resistance have been identified, including: (i) reduced cellular uptake of the platinum salt; (ii) increased repair of platinuminduced DNA damage; (iii) degradation and detoxification of the drugs inside the cells by glutathione; and (iv) altered apoptosis [17, 18].”
BackgroundAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Bronte, G., Rolfo, C., Passiglia, F., Rizzo, S., Gil-Bazo, I., Fiorentino, E., Cajozzo, M., Van Meerbeeck, J. P., Lequaglie, C., Santini, D., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.010 · Cited by 32 · cited 1×
“6 based doublets but, with higher incidence of grade 3-4 hematological toxicities [22].”
Background
Cited by
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Hsu, J. H.-M., Chang, P. M.-H., Cheng, T.-S., Kuo, Y.-L., Wu, A. T.-H., Tran, T.-H., Yang, Y.-H., Chen, J.-M., Tsai, Y.-C., Chu, Y.-S., et al. (2019) · Cancers · doi:10.3390/cancers11071003 · Cited by 68
Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020) · Science Advances · doi:10.1126/sciadv.aba5542 · Cited by 63
Metadata
- Authors
- Rossi, A., & Di Maio, M.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-04-08
- Volume
- 16
- Issue
- 6
- Pages
- 653-660
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2303758877
- Cited by
- 245
- References
- 6
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. https://app.cochat.ai/papers/10.1586/14737140.2016.1170596
- The paper
- Rossi, A., & Di Maio, M. (2016). Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Review of Anticancer Therapy. https://doi.org/10.1586/14737140.2016.1170596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.